MedTrace Logo

Intravenous Methocarbamol for Acute Pain After Spine Surgery

NCT06659965 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1270

Last updated 2025-11-14

No results posted yet for this study

Summary

The goal of this target trial emulation is to evaluate the impact of intravenous (IV) methocarbamol on postoperative pain and opioid use in adults undergoing elective spine surgery. The main questions it aims to answer are:

* Does IV methocarbamol reduce pain in the 6 hours following surgery?
* Does IV methocarbamol decrease the need for opioid pain medications in the same period?

Participants who receive IV methocarbamol as part of their routine postoperative care will have their pain scores and opioid consumption tracked for 6 hours after treatment. Pain levels will be measured using standard assessments, and opioid use will be quantified in oral morphine equivalents.

Conditions

  • Acute Post Operative Pain
  • Postsurgical Pain Management
  • Spine Surgery
  • Acute Pain, Postoperative
  • Multimodal Analgesia

Interventions

DRUG

Intravenous Methocarbamol

At least 500 mg of intravenous methocarbamol administered within 2 hours after the end of elective spine surgery for acute postoperative pain management

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Paul Potnuru, MD · The University of Texas Health Science Center, Houston

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2023-12-31
Completion
2025-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06659965 on ClinicalTrials.gov